Amnon Kahane
Psychiatry · Phoenix, AZNPI 1437194107
Payments from drug & device makers
Across 1,059 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$4K
- Otsuka America Pharmaceutical, Inc.$2K
- Sunovion Pharmaceuticals Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Supernus Pharmaceuticals, Inc.$1K
- Neurocrine Biosciences, Inc.$994
- plus $7K from 25 others
What the payments were for
- Food & beverage$18,39699%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 244 | $3,863 |
| Otsuka America Pharmaceutical, Inc. | 90 | $2,086 |
| Sunovion Pharmaceuticals Inc. | 102 | $1,739 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 89 | $1,429 |
| Supernus Pharmaceuticals, Inc. | 84 | $1,016 |
| Neurocrine Biosciences, Inc. | 27 | $994 |
| Lundbeck LLC | 86 | $980 |
| Johnson & Johnson | 21 | $676 |
| Vanda Pharmaceuticals Inc. | 23 | $660 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $657 |
| Neos Therapeutics, LP | 54 | $641 |
| Almatica Pharma LLC | 29 | $638 |
| Alkermes, Inc. | 17 | $599 |
| Jazz Pharmaceuticals Inc. | 12 | $413 |
| Eisai Inc. | 16 | $340 |
| Teva Pharmaceuticals USA, Inc. | 31 | $321 |
| Idorsia Pharmaceuticals US Inc | 9 | $233 |
| Corium, LLC | 16 | $223 |
| Shire North American Group Inc | 13 | $176 |
| Noven Therapeutics, LLC | 9 | $135 |
| AbbVie | 11 | $133 |
| Ironshore Pharmaceuticals Inc. | 6 | $125 |
| Avanir Pharmaceuticals, Inc. | 6 | $121 |
| Bausch Health US, LLC | 3 | $61 |
| Harmony Biosciences LLC | 2 | $42 |
| Brainsway USA Inc | 1 | $42 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Merck | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 2 | $30 |
| Adlon Therapeutics L.p. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$868
- REXULTI$702
- INGREZZA$691
- ARISTADA$500
- LATUDA$436
- SPRAVATO$396
- CAPLYTA$367
- Fanapt$348
- SUNOSI$235
- QELBREE$230
- Dyanavel XR$170
- ARISTADA INITIO$125
- QUVIVIQ$125
- Dayvigo$125
- VYVANSE$118
- ABILIFY MAINTENA$116
- Austedo XR$103
How this compares
$18,496 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 14 | $19,127 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 149 | $4,193 |
| Lisdexamfetamine Dimesylate | 13 | $2,686 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 37 | $1,230 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $1,014 |
| Ziprasidone Hcl | 14 | $1,012 |
| Alprazolam | 243 | $1,010 |
| Zolpidem Tartrate | 96 | $933 |
| Quetiapine Fumarate | 57 | $901 |
| Hydroxyzine Hcl | 39 | $883 |
| Lamotrigine | 65 | $856 |
| Clonazepam | 130 | $724 |
| Trazodone Hcl | 99 | $604 |
| Gabapentin | 35 | $526 |
| Olanzapine | 17 | $490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,086 | $19,12714 claims |
| Almatica Pharma LLCSertraline Hcl | $638 | $18829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Phoenix
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Ahmed ElmaadawiPhoenix$395K
- Lee KelleyPhoenix$340K
- Eric ReimanPhoenix$160K
- John PraterPhoenix$101K
- Pallavi JoshiPhoenix$62K
- Padma AkingPhoenix$44K
- Mona AminiPhoenix$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.